Moderna shares are down on Monday, pulling back following a recent report highlighting its latest cancer trial results.

If promising results on a skin cancer vaccine from Moderna and Merck lead to a new launch, the Covid-19 era darling's stock could revive after a 91% fall from its peak.

Moderna Inc (NASDAQ:MRNA) shares are trading higher on Wednesday on continued momentum after the company's Tuesday update ...

In the Phase 2b trials, this combination therapy achieved a 49% decrease in the risk of recurrence or death relative to ...

We recently published 10 Stocks Jim Cramer Talked About. Moderna Inc. (NASDAQ:MRNA) is one of the stocks on Jim Cramer talked about. Moderna Inc. (NASDAQ:MRNA)’s shares are up by 16% over the past ...

The pharmaceutical sector continues to attract investor attention, with recent clinical developments highlighting the industry’s innovation potential. Moderna (MRNA) emerged as the top-performing ...

In the latest close session, Moderna (MRNA) was down 1.48% at $47.99. The stock fell short of the S&P 500, which registered a gain of 0.5% for the day. Elsewhere, the Dow gained 0.64%, while the ...

We recently published 10 Stocks Leaving Wall Street in the Dust; 4 Hit Fresh Records. Moderna Inc. (NASDAQ:MRNA) was one of the top performers on Tuesday. Moderna rebounded by 17.02 percent on Tuesday ...

MRNA shares rise after upbeat 2025 sales, stronger cash outlook and detailed 2026 guidance, alongside multiple pipeline milestones.

Moderna MRNA announced that it submitted regulatory filings seeking approval for its seasonal influenza vaccine mRNA-1010 across the United States, European Union, Canada and Australia. These filings ...